ELEV_OUT_1 [2025-04-17 19:48:55 -0400] 4125 Bytes | 1113 tokens | Cum: 1113 tkns (13.91% of 8k)
==========================================================================

Listen up, partner—it's 7:48 PM on Thu Apr 17, 2025, and I’m revved up about Elevation Oncology (ELEV), climbing from $0.3307 to $0.3900. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Elevation Oncology (ELEV)
IPO: 2021-06-25 (3 Years Ago)
Market Cap: $17,397,601
Shares Outstanding: 59,220,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.

Here’s a list of headlines for Elevation Oncology:

Mar-25-25 04:30PM - Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Mar-21-25 01:03PM - Elevation Oncology Plunges 42% on Ending Development of Lead Drug
Mar-21-25 01:03PM 12:01PM - Elevation Oncology downgraded as it halts lead asset on disappointing trials
Mar-20-25 09:09AM - Elevation Oncology slumps on plans to drop cancer candidate
Mar-20-25 09:09AM 08:00AM - Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options
Mar-06-25 04:30PM - Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements
Feb-25-25 07:30AM - Elevation Oncology to Participate in Upcoming Investor Conferences
Jan-15-25 10:10AM - Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-01-15T15:10:00Z - Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
B2 - 2024-01-10T13:02:59Z - Why Aehr Test Systems Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket
B3 - 2024-01-08T18:36:30Z - Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
B4 - 2023-09-29T15:00:34Z - Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
B5 - 2023-06-09T18:56:02Z - Crude Oil Down Over 1%; Planet Labs PBC Shares Tumble
B6 - 2023-06-09T16:49:34Z - Why American Software Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Elevation Oncology (ELEV).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

ELEV_OUT_3 [2025-04-17 19:48:56 -0400] 929 Bytes | 263 tokens | Cum: 1378 tkns (17.22% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-26T16:17:18Z - Elevation Oncology Inc (NASDAQ:ELEV) Downgraded To Equal Weight...
A2 - 2025-03-21T18:08:00Z - Elevation Oncology Plunges 42% on Ending Development of Lead Drug...
A3 - 2025-03-21T16:01:24Z - Elevation Oncology downgraded as it halts lead asset on disappointing trials...
A4 - 2025-03-21T15:34:06Z - Elevation Oncology downgraded as it halts lead asset on disappointing trials By Investing.com...
A5 - 2025-03-21T15:34:05Z - Elevation Oncology downgraded as it halts lead asset on disappointing trials By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ELEV_OUT_5 [2025-04-17 19:48:57 -0400] 1181 Bytes | 317 tokens | Cum: 1697 tkns (21.21% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Elevation Oncology Inc (NASDAQ:ELEV) Downgraded To Equal Weight**Date: 2025-03-26Source: {'uri': 'fxdailyreport.com', 'dataType': 'news', 'title': 'FXDailyReport.Com'}URL: https://fxdailyreport.com/elevation-oncology-inc-nasdaqelev-downgraded-to-equal-weight/Elevation Oncology Inc (NASDAQ:ELEV) stock fell 3.92% (As on March 26, 11:19:48 AM UTC-4, Source: Google Finance) after Stephens downgraded the company to Equal Weight from Overweight with a price target of $1, down from $5, following recent news regarding the discontinuation of development for EO-3021. The company has shifted focus to their in-house developed preclinical asset EO-1022, a HER3-targeting ADC, with preclinical data expected at the AACR Annual Meeting, the firm noted. Wall Street also cut rating on Elevation Oncology Inc after the company announced it will discontinue development of its lead asset, EO-3021, due to

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ELEV_OUT_7 [2025-04-17 19:48:57 -0400] 1181 Bytes | 281 tokens | Cum: 1980 tkns (24.75% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): disappointing efficacy in a Phase 1 trial. Analysts now see limited near-term catalysts, with Elevation pivoting to its HER3-targeted ADC, EO-1022, which is still in preclinical development.

Moreover, Piper Sandler downgraded Elevation to "Neutral" from "Overweight" and slashed its price target to $0.70 from prior levels, citing the company's decision to halt EO-3021's development and focus on EO-1022. While EO-3021 demonstrated differentiated safety, its 22% ORR in monotherapy dose escalation was not enough to justify further development, according to Piper . The firm's new price target reflects projected cash on hand at year-end 2025, with limited upside potential until EO-1022 progresses further. Citizens also moved its rating to "Market Perform" from "Market Outperform," citing the lack of near-term clinical data for EO-1022 and uncertainty around potential strategic transactions.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ELEV_OUT_9 [2025-04-17 19:48:58 -0400] 1181 Bytes | 272 tokens | Cum: 2254 tkns (28.18% of 8k)
==========================================================================

Showing A1 (chunk 3 of 4): The timeline to clinical data for EO-1022 and the unpredictable nature of potential partnerships or mergers make it difficult to assign near-term upside. The firm highlighted that Elevation shares are trading at around 25% of their 4Q24 cash balance, which it views as a fair discount given the current uncertainties. With EO-3021 discontinued, Elevation is shifting focus to EO-1022, a HER3-targeted ADC expected to file for an Investigational New Drug (IND) application in 2026.

Piper noted that preclinical data is expected at the American Association for Cancer Research (AACR) in April, but emphasized that meaningful clinical data remains at least two years away. Elevation is also exploring strategic alternatives, including in-licensing new programs or pursuing a merger. Citizens commented that "if ELEV deploys cash, it plans to remain ADC focused," but the outcome of these efforts is dif

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ELEV_OUT_11 [2025-04-17 19:48:59 -0400] 647 Bytes | 158 tokens | Cum: 2414 tkns (30.18% of 8k)
==========================================================================

Showing A1 (chunk 4 of 4): ficult to predict. Piper and Citizens both noted that Elevation's current valuation reflects its depressed outlook and uncertain strategic future. With $93.2 million in cash and equivalents and around $31 million in debt as of year-end 2024, the company has a cash runway into the second half of 2026, but Piper cautioned that execution and financing risks remain.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ELEV_OUT_13 [2025-04-17 19:49:00 -0400] 1085 Bytes | 281 tokens | Cum: 2697 tkns (33.71% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S2 - 2025-03-06 8-K Item 2.02.

Results of Oper and Fin Cond.

On March 6, 2025, Elevation Oncology, Inc. (the Company) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2024. A copy of the press release is attached as ...

S3 - 2025-03-06 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations together with our CONS financial statements and related notes appearin...

S8 - 2024-11-06 8-K Item 2.02.

Results of Oper and Fin Cond.

On November 6, 2024, Elevation Oncology, Inc. (the Company) issued a press release announcing its financial results for the third quarter ended September 30, 2024. A copy of the press release is attached as Exhibit 99....

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ELEV_OUT_15 [2025-04-17 19:49:03 -0400] 1077 Bytes | 265 tokens | Cum: 2964 tkns (37.05% of 8k)
==========================================================================

Showing S2 (chunk 1 of 1): S2:
Item 2.02.

Results of Operations and Financial Condition.

On March 6, 2025, Elevation Oncology, Inc. (the Company) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this report.

The information furnished in this Item 2.02, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended (the Securities Act), except as expressly set forth by specific reference in such a filing....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ELEV_OUT_17 [2025-04-17 19:49:09 -0400] 7375 Bytes | 2101 tokens | Cum: 5067 tkns (63.34% of 8k)
==========================================================================

This is our set of metrics for Elevation Oncology.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+----------------------+
| Volume: 2,676,341 | Perf Month: -19.21% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+-------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 1.60M | Perf Quarter: -42.35% | Short Float: 15.67% | ROE: -77.48% |
+-------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 1.67 | Index: RUT | Short Ratio: 5.09 | ROI: -48.80% |
+-------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 58.67 | Market Cap: 22.87M | Short Interest: 8.16M | Sales Surprise: - |
+-------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.04 | Shs Outstand: 59.13M | Beta: 1.45 | EPS Surprise: 19.17% |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA20: 39.19% | Shs Float: 52.07M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA50: -12.65% | Inst Own: 65.79% | Sales past 5Y: 0.00% | Earnings: Mar 06 AMC |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA200: -53.97% | Insider Own: 12.09% | Employees: 34 | |
+-------------------+-----------------------+-------------------------+----------------------+
| Perf Week: 42.96% | Insider Trans: 0.00% | Debt/Eq: 0.52 | |
+-------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading by Elevation Oncology officers or majority shareholders (if available).

Inside Trans: Elevation Oncology, Inc. (ELEV) by Ferra Joseph J Jr (CHIEF EXECUTIVE OFFICER) on 2025-03-16
- Common Stock: 12562 shares at $N/A (D)
- Common Stock: 4628 shares at $0.5328 (D)
- Restricted Stock Unit: 12562 shares at $0 (D)

Inside Trans: Elevation Oncology, Inc. (ELEV) by Ferra Joseph J Jr (CHIEF EXECUTIVE OFFICER) on 2025-02-15
- Common Stock: 25000 shares at $N/A (D)
- Common Stock: 9211 shares at $0.6717 (D)
- Stock Option (Right to Buy): 800000 shares at $0 (D)
- Restricted Stock Unit: 25000 shares at $0 (D)

Inside Trans: Elevation Oncology, Inc. (ELEV) by Dornan David (CHIEF SCIENTIFIC OFFICER) on 2025-02-15
- Common Stock: 9375 shares at $N/A (D)
- Common Stock: 4152 shares at $0.6717 (D)
- Restricted Stock Unit: 9375 shares at $0 (D)

Inside Trans: Elevation Oncology, Inc. (ELEV) by Furlong Tammy (CHIEF FINANCIAL OFFICER) on 2025-02-15
- Common Stock: 9375 shares at $N/A (D)
- Common Stock: 2780 shares at $0.6717 (D)
- Common Stock: 300 shares at $N/A (D)
- Common Stock: 89 shares at $0.6717 (D)
- Stock Option (Right to Buy): 275000 shares at $0 (D)
- Restricted Stock Unit: 9375 shares at $0 (D)
- Restricted Stock Unit: 300 shares at $0 (D)

Inside Trans: Elevation Oncology, Inc. (ELEV) by Jansen Valerie Malyvanh (CHIEF MEDICAL OFFICER) on 2025-02-15
- Common Stock: 17500 shares at $N/A (D)
- Common Stock: 5189 shares at $0.6717 (D)
- Stock Option (Right to Buy): 275000 shares at $0 (D)
- Restricted Stock Unit: 17500 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -44485000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.386
Average Volume: 2298625.3
30-Day High: 0.4815
30-Day Low: 0.233

[Detailed Financials: TTM 2024]
- Total Assets: $95,626,000.00
- Total Liabilities: $35,601,000.00
- Total Equity: $60,025,000.00
- Current Assets: $94,726,000.00
- Current Liabilities: $4,467,000.00

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: $-44,485,000.00
- Gross Profit: N/A
- Operating Income: $-44,703,000.00
- Earnings Per Share (EPS): -0.78

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $209,000.00

[Detailed Financials: FY 2024]
- Total Assets: $95,626,000.00
- Total Liabilities: $35,601,000.00
- Total Equity: $60,025,000.00
- Current Assets: $94,726,000.00
- Current Liabilities: $4,467,000.00

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: $-44,485,000.00
- Gross Profit: N/A
- Operating Income: $-44,703,000.00
- Earnings Per Share (EPS): -0.78

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $209,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Elevation Oncology (ELEV).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Elevation Oncology.

2) MARKET_SCORE[]
This conversation was initiated because ELEV is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for ELEV.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, ELEV could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect ELEV to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Elevation Oncology.

11) ETHICAL_RATING[]
Rate Elevation Oncology’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Elevation Oncology.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

ELEV_IN_19 [2025-04-17 19:49:10 -0400] 126 Bytes | 29 tokens | Cum: 5305 tkns (66.31% of 8k)
==========================================================================

====================================
[2025-04-17 19:49:10] # Analysis Completed
Elapsed Time: 15.19 seconds